Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs
J Clin Psychiatry 2013;74(1):e75-e78
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
b-Blockers are prescribed for several indications, including ischemic heart disease, hypertension, heart failure, anxiety, migraine, and essential tremor. Some patients receiving b-blockers for 1 or more of these indications may also require treatment with an antidepressant, such as for comorbid depression. Some antidepressants inhibit the metabolism of some b-blockers; for example, fluoxetine, paroxetine, duloxetine, and bupropion can inhibit cytochrome P450 2D6 and thereby increase the levels of metoprolol, carvedilol, and nebivolol. This pharmacokinetic drug interaction can result in clinically significant bradycardia and hypotension, heart block, or other dose-dependent adverse effects in vulnerable patients. The interaction can be avoided by prescribing an antidepressant that does not affect the metabolism of the b-blocker in use, or by prescribing a b-blocker that is not metabolized by the antidepressant in use. If the interaction is unavoidable, the dose of the b-blocker can be down-titrated using heart rate and blood pressure as a clinical guide.